View in EDS

Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial.

Saved in:
Bibliographic Details
Title: Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial.
Authors: Powles T; Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, St. Bartholomew's Hospital, London, UK. thomas.powles1@nhs.net., Sridhar SS; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada., Loriot Y; Gustave Roussy, INSERMU981, Université Paris-Saclay, Villejuif, France., Bellmunt J; Department of Medical Oncology, Beth Israel Deaconess Medical Center and IMIM-PSMAR Lab, Harvard Medical School, Boston, MA, USA., Mu XJ; Computational Biology, Oncology Research and Development, Pfizer, La Jolla, CA, USA., Ching KA; Computational Biology, Oncology Research and Development, Pfizer, La Jolla, CA, USA., Pu J; Statistics, Global Biometrics and Data Management, Pfizer, La Jolla, CA, USA., Sternberg CN; Englander Institute for Precision Medicine, Weill Cornell Medicine, Hematology/Oncology, Meyer Cancer Center, New York, NY, USA., Petrylak DP; Yale Cancer Center, New Haven, CT, USA., Tambaro R; Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS Fondazione Giovanni Pascale, Naples, Italy., Dourthe LM; Service d'Oncologie Médicale, Clinique St Anne, Strasbourg, France., Alvarez-Fernandez C; Department of Medical Oncology, Hospital Universitario Central de Asturias. Instituto de Investigación Sanitaria del Principado de Asturias, Oviedo, Spain., Aarts M; Department of Medical Oncology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, Netherlands., di Pietro A; Pfizer Italia srl, Milano, Italy., Grivas P; Department of Medicine, Division of Medical Oncology, University of Washington; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, WA, USA., Davis CB; Translational Oncology, Pfizer, La Jolla, CA, USA. craig.davis@pfizer.com.
Source: Nature medicine [Nat Med] 2021 Dec; Vol. 27 (12), pp. 2200-2211. Date of Electronic Publication: 2021 Dec 10.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Nature Publishing Company Country of Publication: United States NLM ID: 9502015 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1546-170X (Electronic) Linking ISSN: 10788956 NLM ISO Abbreviation: Nat Med Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 34893775
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Powles+T%22">Powles T</searchLink>; Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, St. Bartholomew's Hospital, London, UK. thomas.powles1@nhs.net.<br /><searchLink fieldCode="AU" term="%22Sridhar+SS%22">Sridhar SS</searchLink>; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.<br /><searchLink fieldCode="AU" term="%22Loriot+Y%22">Loriot Y</searchLink>; Gustave Roussy, INSERMU981, Université Paris-Saclay, Villejuif, France.<br /><searchLink fieldCode="AU" term="%22Bellmunt+J%22">Bellmunt J</searchLink>; Department of Medical Oncology, Beth Israel Deaconess Medical Center and IMIM-PSMAR Lab, Harvard Medical School, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Mu+XJ%22">Mu XJ</searchLink>; Computational Biology, Oncology Research and Development, Pfizer, La Jolla, CA, USA.<br /><searchLink fieldCode="AU" term="%22Ching+KA%22">Ching KA</searchLink>; Computational Biology, Oncology Research and Development, Pfizer, La Jolla, CA, USA.<br /><searchLink fieldCode="AU" term="%22Pu+J%22">Pu J</searchLink>; Statistics, Global Biometrics and Data Management, Pfizer, La Jolla, CA, USA.<br /><searchLink fieldCode="AU" term="%22Sternberg+CN%22">Sternberg CN</searchLink>; Englander Institute for Precision Medicine, Weill Cornell Medicine, Hematology/Oncology, Meyer Cancer Center, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Petrylak+DP%22">Petrylak DP</searchLink>; Yale Cancer Center, New Haven, CT, USA.<br /><searchLink fieldCode="AU" term="%22Tambaro+R%22">Tambaro R</searchLink>; Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS Fondazione Giovanni Pascale, Naples, Italy.<br /><searchLink fieldCode="AU" term="%22Dourthe+LM%22">Dourthe LM</searchLink>; Service d'Oncologie Médicale, Clinique St Anne, Strasbourg, France.<br /><searchLink fieldCode="AU" term="%22Alvarez-Fernandez+C%22">Alvarez-Fernandez C</searchLink>; Department of Medical Oncology, Hospital Universitario Central de Asturias. Instituto de Investigación Sanitaria del Principado de Asturias, Oviedo, Spain.<br /><searchLink fieldCode="AU" term="%22Aarts+M%22">Aarts M</searchLink>; Department of Medical Oncology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, Netherlands.<br /><searchLink fieldCode="AU" term="%22di+Pietro+A%22">di Pietro A</searchLink>; Pfizer Italia srl, Milano, Italy.<br /><searchLink fieldCode="AU" term="%22Grivas+P%22">Grivas P</searchLink>; Department of Medicine, Division of Medical Oncology, University of Washington; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, WA, USA.<br /><searchLink fieldCode="AU" term="%22Davis+CB%22">Davis CB</searchLink>; Translational Oncology, Pfizer, La Jolla, CA, USA. craig.davis@pfizer.com.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229502015%22">Nature medicine</searchLink> [Nat Med] 2021 Dec; Vol. 27 (12), pp. 2200-2211. <i>Date of Electronic Publication: </i>2021 Dec 10.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Publishing+Company%22">Nature Publishing Company </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9502015 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1546-170X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2210788956%22">10788956 </searchLink><i>NLM ISO Abbreviation: </i>Nat Med <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=34893775
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s41591-021-01579-0
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 2200
    Titles:
      – TitleFull: Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Powles T
      – PersonEntity:
          Name:
            NameFull: Sridhar SS
      – PersonEntity:
          Name:
            NameFull: Loriot Y
      – PersonEntity:
          Name:
            NameFull: Bellmunt J
      – PersonEntity:
          Name:
            NameFull: Mu XJ
      – PersonEntity:
          Name:
            NameFull: Ching KA
      – PersonEntity:
          Name:
            NameFull: Pu J
      – PersonEntity:
          Name:
            NameFull: Sternberg CN
      – PersonEntity:
          Name:
            NameFull: Petrylak DP
      – PersonEntity:
          Name:
            NameFull: Tambaro R
      – PersonEntity:
          Name:
            NameFull: Dourthe LM
      – PersonEntity:
          Name:
            NameFull: Alvarez-Fernandez C
      – PersonEntity:
          Name:
            NameFull: Aarts M
      – PersonEntity:
          Name:
            NameFull: di Pietro A
      – PersonEntity:
          Name:
            NameFull: Grivas P
      – PersonEntity:
          Name:
            NameFull: Davis CB
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 12
              Text: 2021 Dec
              Type: published
              Y: 2021
          Identifiers:
            – Type: issn-electronic
              Value: 1546-170X
          Numbering:
            – Type: volume
              Value: 27
            – Type: issue
              Value: 12
          Titles:
            – TitleFull: Nature medicine
              Type: main
ResultId 1